Pricing plans revealed for now COVID-19 treatment
Gilead Sciences announces pre-order pricing plans for coronavirus (COVID-19) treatment, remdesivir, to be offered to patients starting in July. The pharmaceutical company will be donating doses to the U.S. government after authorizing emergency use in May.
Gilead Sciences are set to price remdesivir for U.S. private insurance companies for $520 per vial and for governments “of developed countries” around the world for $390 per vial. Gilead Sciences wants to offer pricing options for all economic classes for everyone to access including lower prices for government programs like Medicare.
This pharmaceutical company will be offering remdesivir to everyone whether or not have a patient has insurance with some uninsured to be covered under the provisions of the CARES Act. People who are privately insured will have out-of-pocket costs to be determined by certain insurance plans.
Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient on Private Insurance
"Under the company’s plans, Gilead will charge a higher price for patients with private insurance in the U.S., and a lower price for U.S. government health programs"
https://t.co/JZmEPP2Y0g— David Jolly (@DavidJollyFL) June 29, 2020
Gilead Sciences will provide remdesivir at a lower cost through agreements with generic manufacturers. A majority of patients being treated with remsesivir will need six vials over a five-day treatment plan. Prices for the five-day treatment will cost $3,120 for commercial insurance patients and $2,340 for government cost patients.
Some patients will require a longer, 10-day treatment and needed 11 vials that can cost $5,720 for a U.S. patient with private insurance or a patient with government costs of $4,290. Scientists are seeing success in recovery time treating severely ill COVID-19 patients with remdesivir, but the FDA has yet to officially approve any COVID-19 treatments.
This COVID-19 treatment is expected to save nearly $12,000 per patient due to early hospital discharge with recovery from the remdesivir treatment. Gilead Sciences is continuing testing and developing a better course of treatment for higher chances of recovery.
-
Deportation Deadline Sparks Humanitarian Worries in Pakistan Pakistan’s government announced on Monday that almost 200,000 Afghan nationals have voluntarily...
-
Lessons Learned Shape Taiwan’s Preparedness in a Changing World Taiwan’s military has embarked on a comprehensive initiative to strengthen...
-
White House Reveals Disturbing Executions and Threats in Conflict The White House has disclosed deeply concerning information regarding the...
-
Military Exercises Coincide with Treaty Developments Amid Global Concerns Russia recently executed a large-scale military exercise to rehearse its...
-
Company Addresses Auto-Translation Error Impacting Palestinian Users Meta, the parent company of Instagram, has issued a formal apology for...
-
China’s Ambitious Plans to Double Its Nuclear Warhead Stockpile Highlighted in Pentagon’s Annual Report The annual report released by...
-
Strengthening Partnerships and Providing Support in Challenging Times In a collaborative effort between the U.S. Congress and the White...
-
Humza Yousaf Extends Support and Sanctuary Amidst Gaza Conflict Humza Yousaf, the First Minister of Scotland, has extended a...
-
U.S. Stresses Peace and Humanitarian Aid in Israeli-Palestinian Conflict In an exclusive interview aired on Sunday, President Joe Biden...
-
Urgent Call for Aid as Communities Reel from Tremors The western province of Herat in Afghanistan has been rocked...
-
Calls for Peace Amid Diverse Perspectives on Ongoing Crisis In response to a series of recent demonstrations across Canada,...
-
Celebrity Voices in the Israel-Palestine Dialogue In the midst of the ongoing Israel-Palestine conflict, a group of celebrities has...